Quetiapine Accord 25 mg film - coated tablets Բուլղարիա - բուլղարերեն - Изпълнителна агенция по лекарствата

quetiapine accord 25 mg film - coated tablets

accord healthcare limited - 25 mg film - coated tablets

Etoposide Accord 20 mg/ml concentrate for solution for infusion Բուլղարիա - բուլղարերեն - Изпълнителна агенция по лекарствата

etoposide accord 20 mg/ml concentrate for solution for infusion

accord healthcare limited - Этопозид - 20 mg/ml concentrate for solution for infusion

Paclitaxel Accord 6 mg/ml concentrate for solution for infusion Բուլղարիա - բուլղարերեն - Изпълнителна агенция по лекарствата

paclitaxel accord 6 mg/ml concentrate for solution for infusion

accord healthcare limited - Паклитаксел - 6 mg/ml concentrate for solution for infusion

Cisplatin Accord 1 mg/ml concentrate for solution for infusion Բուլղարիա - բուլղարերեն - Изпълнителна агенция по лекарствата

cisplatin accord 1 mg/ml concentrate for solution for infusion

accord healthcare limited - Цисплатин - 1 mg/ml concentrate for solution for infusion

Oxaliplatin Accord 5 mg/ml concentrate for Solution for infusion Բուլղարիա - բուլղարերեն - Изпълнителна агенция по лекарствата

oxaliplatin accord 5 mg/ml concentrate for solution for infusion

accord healthcare limited - 5 mg/ml concentrate for solution for infusion

Fluorouracil Accord 50 mg/ml solution for injection or infusion Բուլղարիա - բուլղարերեն - Изпълнителна агенция по лекарствата

fluorouracil accord 50 mg/ml solution for injection or infusion

accord healthcare limited - Фторурацил - 50 mg/ml solution for injection or infusion

Irbesartan Accord 300 mg film-coated tablets Բուլղարիա - բուլղարերեն - Изпълнителна агенция по лекарствата

irbesartan accord 300 mg film-coated tablets

accord healthcare limited - 300 mg film-coated tablets

Orgovyx Եվրոպական Միություն - բուլղարերեն - EMA (European Medicines Agency)

orgovyx

accord healthcare s.l.u. - relugolix - Простатни неоплазми - Ендокринна терапия - orgovyx is indicated for the treatment of adult patients with advanced hormone-sensitive prostate cancer.

Zolsketil pegylated liposomal Եվրոպական Միություն - բուլղարերեն - EMA (European Medicines Agency)

zolsketil pegylated liposomal

accord healthcare s.l.u. - doxorubicin hydrochloride, liposomal - ovarian neoplasms; sarcoma, kaposi; multiple myeloma - doxorubicin - zolsketil pegylated liposomal is a medicine used to treat the following types of cancer in adults:• breast cancer that has spread to other parts of the body in patients at risk of heart problems. zolsketil pegylated liposomal is used on its own for this disease;• advanced ovarian cancer in women whose previous treatment including a platinum-based cancer medicine has stopped working;• multiple myeloma (a cancer of the white blood cells in the bone marrow), in patients with progressive disease who have received at least one other treatment in the past and have already had, or are unsuitable for, a bone marrow transplantation. zolsketil pegylated liposomal is used in combination with bortezomib (another cancer medicine);• kaposi’s sarcoma in patients with aids who have a very damaged immune system. kaposi’s sarcoma is a cancer that causes abnormal tissue to grow under the skin, on moist body surfaces or on internal organs. zolsketil pegylated liposomal contains the active substance doxorubicin and is a ‘hybrid medicine’. this means that it is similar to a ‘reference medicine’ containing the same active substance called adriamycin. however, in zolsketil pegylated liposomal the active substance is enclosed in tiny fatty spheres called liposomes, whereas this is not the case for adriamycin.

Granpidam Եվրոպական Միություն - բուլղարերեն - EMA (European Medicines Agency)

granpidam

accord healthcare s.l.u. - силденафил цитрат - Хипертония, белодробна - urologicals - adultstreatment възрастни пациенти с белодробна артериална хипертония, които са класифицирани като функционален клас ii и iii, за да се подобри капацитетът на тренировка. Ефикасността е доказана при първична белодробна хипертония и белодробна хипертония, свързана със заболяване на съединителната тъкан. Детска populationtreatment педиатрични пациенти на възраст от 1 година до 17 години с белодробна артериална хипертония. Ефикасността по отношение на подобряването на капацитета за физическа активност или белодробната хемодинамика е показана при първична белодробна хипертония и белодробна хипертония, свързана с вродена сърдечна болест.